|

|

|
EMBARGOED FOR RELEASE
Thursday, Sept. 6, 2001
2:00 p.m. Eastern Time
Jeff Minerd
(301) 402-1663
jminerd@niaid.nih.gov
|
A Small
Genetic Change Makes Flu Virus Deadly
A tiny change in one of the influenza virus's 10 genes is key to making
certain strains of the virus especially virulent to humans, scientists
report in the Sept. 7 issue of Science. This discovery helps
explain why an influenza outbreak four years ago in Hong Kong killed an
unusually high proportion of the people it infected - six out of 18, says
lead researcher Yoshihiro Kawaoka, D.V.M., Ph.D., of the University of
Wisconsin-Madison.
"We have found that a limited number of very tiny genetic changes in a
specific gene, one called PB2, can have a big effect on how potent the
influenza virus is," says Dr. Kawaoka, a grantee of the National
Institute of Allergy and Infectious Diseases (NIAID). "Because the
influenza virus constantly mutates, and because only a few changes can make
a non-pathogenic virus highly pathogenic, we should assume that an outbreak
of any new strain or subtype is potentially dangerous to humans."
"To prepare for future influenza pandemics, NIAID has supported
efforts to understand how new virus strains potentially harmful to humans
appear," says Anthony S. Fauci, M.D., NIAID director. "This study
is an elegant example of research that provides insight into the emergence
of virulent viruses and can help us develop better strategies for detecting
future outbreaks."
Wild waterfowl are natural reservoirs for the influenza virus; these birds
transmit the virus to pigs or chickens, which then pass it on to people.
The deadly outbreak of influenza virus subtype H5N1 in Hong Kong in 1997
was the first documented case of an influenza virus jumping directly from
chickens to people. Public health authorities responded by ordering the
slaughter of more than 1 million live poultry to prevent further spread of
the virus to humans.
Dr. Kawaoka and colleagues obtained samples of the H5N1 viruses that had
infected Hong Kong residents during the 1997 outbreak. Testing these
viruses in laboratory mice, the researchers found good correlation between
how sick certain H5N1 strains made mice and how sick they had made humans.
The researchers divided the H5N1 strains into two groups: one that caused
systemic lethal infection in the mice and one that was relatively benign.
Mice are a good model for studying H5N1, Dr. Kawaoka says, because this
virus affects mice and humans similarly.
Next, Dr. Kawaoka used a technology that allows him to genetically engineer
"designer" influenza viruses from scratch. By systematically
swapping the genes from the harmful and benign viruses, then testing how
those engineered viruses affected mice, he discovered that the PB2 gene
from the harmful group gives the virus its potency. Then, through testing
viruses that contained variations of this PB2 gene, he further identified a
tiny change within the gene - a change of just one unit of RNA - that
appears to be key to the virus's virulence.
The function of the PB2 gene is not completely understood, but scientists
believe it codes for an enzyme that helps force the host cell's molecular
machinery to make more viruses, Dr. Kawaoka explains. "We don't know
if the mutation we studied is involved in that process, but our next step
will be to find out," he says.
Just over 10 years ago, researchers developed the ability to genetically
engineer influenza viruses, a process known as reverse genetics. In 1999,
Dr. Kawaoka, with support from NIAID, streamlined this technology, making
it much more efficient. Without the ability to engineer influenza viruses
through the reverse genetics system, it would not have been possible to
create and study variations of the H5N1 virus, Dr. Kawaoka says. "Just
a few years ago, this discovery would not have been possible," says
Carole Heilman, Ph.D., director of NIAID's Division of Microbiology and
Infectious Diseases. "We believe this is the first of many more
important discoveries that will arise from this technology."
For more information on Dr. Kawaoka's work in this field, other
NIAID-supported influenza research, and background on the virus itself,
visit Focus on the Flu on the NIAID Web site at http://www.niaid.nih.gov/newsroom/focuson/flu00.
Focus on the Flu also contains information on NIAID-sponsored
efforts to prepare for future influenza pandemics. Such efforts include
helping to fund ongoing monitoring of influenza virus strains circulating
through live poultry markets in Hong Kong, a project that could nip future
outbreaks in the bud. Other NIAID-supported researchers are examining the
history of influenza virus evolution for clues about which new strains
might emerge next.
###
Reference: Hatta M et al.
Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science
293(5536):1840-42 (2001).
NIAID
is a component of the National Institutes of Health (NIH). NIAID conducts
and supports research to prevent, diagnose and treat illnesses such as HIV
disease and other sexually transmitted diseases, tuberculosis, malaria,
asthma and allergies. NIH is an agency of the U.S. Department of Health and
Human Services.
Press
releases, fact sheets and other NIAID-related materials are available on
the NIAID Web site at http://www.niaid.nih.gov.
Search | Home | News Releases
Last
updated September 6, 2001 (sas)
|